Paratek Announces Pricing of Public Offering of Common Stock
January 18 2018 - 9:41AM
Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical
company focused on the development and commercialization of
innovative therapies based upon its expertise in novel tetracycline
chemistry, today announced that it has sold 3,205,128 shares of its
common stock in a registered underwritten public offering for total
proceeds of approximately $50 million. The offering is expected to
close on January 22, 2018, subject to customary closing conditions.
All of the shares sold in the offering were sold by Paratek. In
addition, Paratek has granted the underwriter a 30-day option to
purchase up to an additional 480,769 shares of its common stock.
BTIG, LLC is acting as sole book-running manager for the
offering.
A shelf registration statement on Form S-3 relating to the
public offering of the shares of common stock described above was
declared effective by the Securities and Exchange Commission (SEC)
on October 29, 2015. Before you invest, you should read the
prospectus in the registration statement and related prospectus
supplement that Paratek will file with the SEC for more complete
information about Paratek and this offering. An electronic copy of
the prospectus supplement and accompanying prospectus relating to
the offering will be available on the website of the SEC at
www.sec.gov. Copies of the prospectus supplement, when available,
and the accompanying prospectus relating to the offering may be
obtained by contacting BTIG, LLC, at 825 Third Avenue, 6th Floor,
New York, NY, 10022, or by telephone at (212) 593-7555 or by e-mail
at equitycapitalmarkets@btig.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a clinical stage
biopharmaceutical company focused on the development and
commercialization of innovative therapeutics based upon
tetracycline chemistry. Paratek has used its expertise in biology
and tetracycline chemistry to create chemically diverse and
biologically distinct small molecules derived from the minocycline
core structure. Paratek’s two lead product candidates are the
antibacterials, omadacycline and sarecycline.
CONTACTS:
Media Relations: |
|
Investor Relations: |
Michael Lampe |
|
Hans
Vitzthum |
(484)
575-5040 |
|
LifeSci Advisors, LLC. |
michael@scientpr.com |
|
212-915-2568 |
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2023 to Apr 2024